Cassava Sciences Inc vs Lithium Americas Corp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Lithium Americas Corp trades at $3.27 (market cap $1.18B). The key difference: Lithium Americas Corp is far larger — about 24.7× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| FLNA | LAC | |
|---|---|---|
Market Cap | $47.75M | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $10.05 |
52-Week Low | $0.87 | $2.71 |
Enterprise Value | -$34.93M | $1.29B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lithium Americas (LAC) trades at $3.23, up 6.95% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $122.09 million for 2025 and continues to burn cash from operations. Recent news highlights $175 million financing for Thacker Pass construction, providing balance sheet support amid ongoing capital expenditures exceeding $900 million annually.
While analyst consensus leans positive with no sell ratings, significant execution risks persist as LAC navigates peak construction phase. The stock faces headwinds from negative ROE (-11.35%) and cash burn, though strategic positioning in lithium development offers long-term potential if project timelines and funding are successfully managed.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →